The faces of Dynamic42: Senior Scientist Rizwan
Earlier this year, Senior Scientist Dr. Rizwan Rehimi joined Dynamic42 for a joint project with the Institute of Pharmaceutical Biology and Biotechnology at Heinrich Heine University in Düsseldorf, Germany. As part of the research group of Prof. Dr. Nicole Teusch (HHU), Rizwan supports the development of 3D tumor models for drug testing.
Support with many years of experience in cell biology
Rizwan studied at the University of Punjab, Lahore in Pakistan until 2002. There he completed his master’s degree in zoology before coming to Germany for his further scientific career. He obtained his PhD at the Institute of Anatomy and Cell Biology, University of Freiburg, Germany, in the Department of Molecular Embryology. During this time, his research focused on the study of cells during vertebrate embryo development.
He then started his first postdoc in the Neuromuscular Laboratory of the University Hospital Bergmannsheil of the Ruhr-University Bochum. There, he particularly investigated the role of multiple molecules of the innate and adaptive immune system in sufferers of the muscle disease myositis.
In 2013, Rizwan started his second postdoctoral position at the Center for Molecular Medicine in Cologne (CMMC). The focus of his research there was on the use of epigenetic and developmental biology techniques to identify cell identity regulators. These are relevant in embryonic axis formation.
Now Rizwan is temporarily part of our team as a visiting scientist. We are pleased to add energetic support and many years of scientific and research experience with him.
``I am excited to bring my expertise from cell biology and analytics to Dynamic42. The development of a human 3D tumor-on-chip model will significantly improve the testing of drugs and immunotherapies. I am very motivated to be able to contribute to this biotechnological innovation.`` - Dr. Rizwan Rehimi, Senior Scientist
More interesting articles:
Summary of our work that established a human liver microphysiological model as an in vitro platform for the evaluation of drug-induced liver injury.Read More